Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Crest Nicholson holds guidance amid falling mortgage costs

(Sharecast News) - House builder Crest Nicholson on Thursday held annual guidance after a rise in adjusted half-year earnings amid an easing in mortgage costs as interest rates fall. Adjusted pre-tax profit rose to £7.9m from £2.6m. Completions fell to 739 from 788 as the company switched focus to open market homes in the mid premium segment to increase profitability. Forward orders for the full year were 763 units at the end of May.

On a statutory basis, the company swung to a £9.4m profit after a £31m loss last year.

"Trading in the first half of the financial year was in line with expectations with a stronger than anticipated balance sheet position at the period end. sales have continued to progress in line with expectations in the first few weeks of the second half of the financial year," the company said.

"We remain mindful of volatility in the macroeconomic backdrop, which continues to impact consumers through concerns around affordability and job security. However, the market is now starting to benefit from increased lender support and better mortgage affordability as the interest rate environment starts to ease."

"Planning reforms continue to move slowly but positively. As such, we anticipate further stabilisation in the trading environment in the second half of the year."

Crest added that it was not experiencing any major build cost inflationary pressures, either from wages or materials prices.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.